Oregon Center for Complementary and Alternative Medicine in Neurological Disorders
NCT00010881 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL
Last updated 2006-08-18
Summary
The mission of the Oregon Center for Complementary and Alternative Medicine in Neurological Disorders (ORCCAMIND) is to facilitate research and education on the effectiveness and mechanisms of action of complementary and alternative medicine (CAM) therapies in the treatment of neurological disorders. The integration of conventional medicine and CAM communities is critical for the success of ORCCAMIND. Thus, ORCCAMIND is composed of six institutions: Oregon Health Sciences University; National College of Naturopathic Medicine; Western States Chiropractic College; Oregon College of Oriental Medicine; the Linus Pauling Institute at Oregon State University; and the Portland Veterans Affairs Medical Center.
ORCCAMIND will initially focus on the use of CAM antioxidants and stress reduction as treatments for neurodegenerative and demyelinating diseases because many of these diseases have oxidative injury as a causative or contributory factor and several CAM approaches have direct or indirect anti-oxidant effects. Through the Career Development Program the Developmental Research Program and the activities of the Education and Information Core, we will also foster and promote research into other CAM approaches for neurologic diseases that extend beyond anti-oxidant therapies. ORCCAMIND will achieve its goals by carrying out 4 Research Projects and maintaining 4 Core facilities that integrate the research strengths of conventional medicine and CAM practitioners and researchers. ORCCAMIND draws its strength from the multi-institutional support and the quality of all its investigators. The investigators join ORCCCAMIND with extensive experience with clinical trials, patient care, externally funded basic and clinical neuroscience research, and training programs, including federally-funded training grants. ORCCAMIND is a bold initiative that integrates basic and clinical research scientists, conventional neurologists and CAM practitioners. It will promote the exploration of new areas of CAM research and lead research on CAM therapies for neurological disorders.
Conditions
Interventions
- DRUG
-
antioxidants
- BEHAVIORAL
-
stress reduction
Sponsors & Collaborators
-
National Center for Complementary and Integrative Health (NCCIH)
lead NIH
Principal Investigators
-
Dr. Barry S. Oken · Oregon Health and Science University
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-30
- Completion
- 2004-12-31
Countries
- United States
Study Locations
More Related Trials
-
Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder
NCT06969937 ·Status: RECRUITING ·Phase: PHASE2
-
Neuroimmune Dysfunction in Alcohol Use Disorder
NCT04210713 ·Status: COMPLETED ·Phase: PHASE1
-
The Neural Correlates of Cannabis Use
NCT03104257 ·Status: COMPLETED
-
A Pilot Study of Non-invasive Brain Stimulation to Boost the Efficacy of Psychotherapy in a Community Sample of People Who Drink Alcohol
NCT04770025 ·Status: RECRUITING ·Phase: PHASE2
-
Neurofeedback Training of Metacognition in Subjects With Alcohol Use Disorder. Disorder Induces Neural Modifications: an Event-related Potentials Study
NCT05913518 ·Status: RECRUITING ·Phase: NA
-
Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)
NCT01030835 ·Status: COMPLETED
-
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
NCT05855668 ·Status: RECRUITING ·Phase: NA
-
Development of a Selective ALDH2 Inhibitor to Treat AUD
NCT04311294 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
NCT06349083 ·Status: RECRUITING ·Phase: PHASE2
-
Neuromodulation and Mindfulness Patients With AUD
NCT06308484 ·Status: RECRUITING ·Phase: NA
-
Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
NCT00218725 ·Status: COMPLETED ·Phase: PHASE1
-
Neurobiological Mechanisms of Chess as an Add-On Treatment Against SUD
NCT04057534 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
NCT00218517 ·Status: COMPLETED ·Phase: PHASE2
-
Alcohol and Neural Cardiovascular Control in Binge Drinkers
NCT03567434 ·Status: COMPLETED ·Phase: NA
-
Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder
NCT05656534 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neurobiology of Alcohol and Nicotine Co-Addiction
NCT03338933 ·Status: COMPLETED
-
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
NCT06160232 ·Status: RECRUITING ·Phase: PHASE2
-
Cerebellar Alterations in Individuals With a Cannabis Use Disorder
NCT02816034 ·Status: COMPLETED ·Phase: NA
-
Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission
NCT02147483 ·Status: COMPLETED ·Phase: NA
-
Neurofeedback Training for the Treatment of Substance Use Disorders
NCT03356210 ·Status: COMPLETED ·Phase: NA
-
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
NCT04410913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
NCT03253926 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes
NCT00926900 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pharmacological Treatment for Alcoholism
NCT00382642 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00102596 ·Status: COMPLETED ·Phase: PHASE2